title: Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression.
abstract: We examined the relevance of a pre-treatment single static view 99mTc-sestamibi scintimammography and expression of multidrug resistance proteins as predictors of response to neoadjuvant chemotherapy for invasive breast cancer. Forty-five patients affected by primary breast cancer underwent clinical examination, mammography, sonography, 99mTc-sestamibi scintimammography, and biopsy for histopathological diagnosis before neoadjuvant chemotherapy. Expression of MDR1 and MRP mRNA were determined by RT-PCR on fine-needle aspirations. Following completion of anthracycline-based chemotherapy, clinical, mammographic, sonographic and pathological responses were determined. 99mTc-sestamibi scintimammography predicted the reduction of tumor size measured by sonography and the pathological response according to Sataloff classification (p<0.05) and tend to predict pathological response according to Chevallier (p<0.1). A negative 99mTc-sestamibi scintimammography predicted chemoresistance with a specificity of 100%. Uptake of 99mTc-sestamibi was inversely correlated to the expression of MDR1 (p<0.05) in invasive ductal carcinoma. A pre-treatment single-view 99mTc-sestamibi scintimammography is an excellent predictor of MDR1 chemoresistance and was highly specific of a lack of pathological response to chemotherapy.
authors.affiliation: Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, France. top@cjp.u-clermont1.fr
authors.forename: Anne
authors.initials: A
authors.lastname: Cayre
authors.forename: Florent
authors.initials: F
authors.lastname: Cachin
authors.forename: Jean
authors.initials: J
authors.lastname: Maublant
authors.forename: Danièle
authors.initials: D
authors.lastname: Mestas
authors.forename: Viviane
authors.initials: V
authors.lastname: Feillel
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Ferrière
authors.forename: Fabrice
authors.initials: F
authors.lastname: Kwiaktowski
authors.forename: Sylvie
authors.initials: S
authors.lastname: Chevillard
authors.forename: Françoise
authors.initials: F
authors.lastname: Finat-Duclos
authors.forename: Pierre
authors.initials: P
authors.lastname: Verrelle
authors.forename: Frédérique
authors.initials: F
authors.lastname: Penault-Llorca
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000096:biosynthesis; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008327:Mammography / Q000379:methods*; D008562:Membrane Glycoproteins; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi / Q000494:pharmacology*; D060245:Tetraspanin 29
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D015703:Antigens, CD; C554869:CD9 protein, human; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D060245:Tetraspanin 29; D017256:Technetium Tc 99m Sestamibi